IPF biotech Celea gets $180M to follow paths of PureTech's Karuna, Seaport
IPF biotech Celea gets $180M to follow paths of PureTech's Karuna, Seaport — Endpoints News coverage of biopharma industry developments.
Karuna Therapeutics
NASDAQ: KRTX ~$12B MCAP
Karuna Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for neuropsychiatric disorders, with a focus on muscarinic receptor-targeted treatments.
Company Info
Sector:Biopharmaceutical
Headquarters:Boston, Massachusetts, United States
Founded:2009
Website:www.karunatx.com/
Upcoming Milestones & Key Dates
2026-Q4
Clinical
KarXT Alzheimer's psychosis data expected
Clinical Development Pipeline
KarXT
Target: Muscarinic M1/M4 receptorsKarXT
Target: Muscarinic M1/M4 receptorsKarXT
Target: Muscarinic M1/M4 receptorsRecent News
Leadership Team
Steve Paul
Chief Executive Officer
Andrew Miller
Chief Financial Officer
Stephen Brannan
Chief Medical Officer